Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Current Signal: BUY (auto-tracking)
2.68% $4.98
America/New_York / 28 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 687.98 mill |
EPS: | -0.330 |
P/E: | -15.09 |
Earnings Date: | May 12, 2024 |
SharesOutstanding: | 138.15 mill |
Avg Daily Volume: | 0.818 mill |
RATING 2024-03-28 |
---|
B |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Sell | |
Return On Equity: | Sell | |
Return On Asset: | Neutral | |
DE: | Buy | |
P/E: | Strong Sell | |
Price To Book: | Strong Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gr.Profit | n/a | |||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -15.09 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-2.57x |
Company: PE -15.09 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$-0.0009 (-100.02%) $-4.98 |
Date: 2024-03-29 |
Expected Trading Range (DAY) |
---|
$ 4.73 - 5.23 ( +/- 5.02%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-12-28 | Pauls Matthew | Sell | 84 000 | Common Stock |
2023-12-28 | Pauls Matthew | Sell | 19 000 | Common Stock |
2023-12-28 | Lowrance David L | Sell | 10 000 | Common Stock |
2023-12-28 | Elam Nevan C | Buy | 40 000 | Common Stock |
2023-12-28 | Elam Nevan C | Buy | 12 000 | Common Stock |
INSIDER POWER |
---|
84.84 |
Last 97 transactions |
Buy: 8 201 114 | Sell: 569 381 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $4.98 (2.68% ) |
Volume | 0.904 mill |
Avg. Vol. | 0.818 mill |
% of Avg. Vol | 110.49 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $4.77 | N/A | Active |
---|
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.